Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc Natl Acad Sci USA

University of California, San Francisco, San Francisco, California, United States
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 07/2003; 100(13):7803-7. DOI: 10.1073/pnas.1232448100
Source: PubMed


TASK3 gene (Kcnk9) is amplified and overexpressed in several types of human carcinomas. In this report, we demonstrate that a point mutation (G95E) within the consensus K+ filter of TASK3 not only abolished TASK3 potassium channel activity but also abrogated its oncogenic functions, including proliferation in low serum, resistance to apoptosis, and promotion of tumor growth. Furthermore, we provide evidence that TASK3G95E is a dominant-negative mutation, because coexpression of the wild-type and the mutant TASK3 resulted in inhibition of K+ current of wild-type TASK3 and its tumorigenicity in nude mice. These results establish a direct link between the potassium channel activity of TASK3 and its oncogenic functions and imply that blockers for this potassium channel may have therapeutic potential for the treatment of cancers.

Download full-text


Available from: Timothy Hoey
  • Source
    • "1-Lesage et al. 1996; 2-Nie et al. 2005; 3-Beitzinger et al. 2008; 4-Ma et al. 2011; 5-Chavez et al. 1999; 6-Pountney et al. 1999; 7-Patel et al. 2000; 8-Lloyd et al. 2011; 9-Pandit et al. 2014; 10-Salinas et al. 1999; 11-Yost et al. 2008; 12-Fink et al. 1996; 13-Lauritzen et al. 2005; 14-Heurteaux et al. 2006; 15-Heurteaux et al. 2004; 16-Bittner et al. 2013; 17-Blondeau et al. 2007; 18-Garry et al. 2007; 19- Alloui et al. 2006; 20-Pereira et al. 2014); 21-Noël et al. 2009; 22-Voloshyna et al. 2008; 23-Lesage et al. 2000; 24-Bang et al. 2000; 25-Fink et al. 1998; 26-Laigle et al. 2012; 27-Duprat et al. 1997; 28-Heitzmann et al. 2008; 29-Bittner et al. 2009; 30-Davies et al. 2008; 31-Guagliardo et al. 2012; 32-Penton et al. 2012; 33-Lauritzen et al. 2003; 34-Ma et al. 2013; 35-Liang et al. 2014; 36-Mu et al. 2003; 37-Pei et al. 2003; 38-Kim et al. 2000; 39-Rajan et al. 2000; 40-Linden et al. 2007; 41-Bando et al. 2014; 42-Gotter et al. 2011; 43-Barel et al. 2008; 44-Kim & Gnatenco 2001; 45-Ashmole et al. 2001; 46-Reyes et al. 1998; 47-Warth et al. 2004; 48-Barriere et al. 2003; 49-Bobak et al. 2011; 50-Gestreau et al. 2010; 51-Alvarez-Baron et al. 2011; 52-Girard et al. 2001; 53-Friedrich et al. 2014; 54- Rajan et al. 2001; 55-Sano et al. 2003; 56-Chae et al. 2010; 57-Lafrenière et al. 2010; 58-Maher et al. 2013. F (2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: K+ channels participate in many biological functions from ion homeostasis to generation and modulation of the electrical membrane potential. They are involved in a large variety of diseases. In the human genome, 15 genes code for K+ channels with two pore-domains (K2P). These channels form dimers of pore-forming subunits that produce background conductances finely regulated by a range of natural and chemical effectors, including signaling lipids, temperature, pressure, pH, antidepressants and volatile anesthetics. Since the cloning of TWIK1, the prototypical member of this family, a lot of work has been carried out about their structure and biology. These studies are still in progress, but data gathered so far show that K2P channels are central players in many processes including ion homeostasis, hormone secretion, cell development and excitability. A growing number of studies underline their implication in physiopathological mechanisms such as vascular and pulmonary hypertension, cardiac arrhythmias, nociception, neuroprotection and depression. This review gives a synthetic view of the most noticeable features of these channels.This article is protected by copyright. All rights reserved
    Full-text · Article · Dec 2014 · The Journal of Physiology
  • Source
    • "ing cells , it is clear that not all members of the K 1 channel superfamily can support these roles . Only a select group of K 1 channels [ K v 1 . 3 , K 2P 9 . 1 , human ether - à - go - go ( hEAG1 ) , hEAG2 , hERG1 ) ] influence proliferation and have been linked to cancer ( Bianchi et al . , 1998 ; Pardo et al . , 1999 ; Fraser et al . , 2003 ; Pei et al . , 2003 ; Preussat et al . , 2003 ; Tajima et al . , 2006 ; Huang et al . , 2012 ) , suggesting that channel properties other than K 1 selectivity are important . Intriguingly , of this small group , hERG1 , hEAG1 , and hEAG2 belong to the same subfamily and are closely related . Eliminating the K 1 permeation of hEAG1 channels by mutations of "
    [Show abstract] [Hide abstract]
    ABSTRACT: hERG1 and the closely related hEAG1 channel are aberrantly expressed in a large proportion of human cancers. In the present study we demonstrate that transfection of hERG1 into mouse fibroblasts is sufficient to induce many features characteristic of malignant transformation. Importantly, this transformation could be reversed by chronic incubation (for 2-3 weeks) with the hERG channel blocker dofetilide (100nM), while more acute applications (for 1-2 days) were ineffective. hERG1 expression resulted in a profound loss of cell contact inhibition, multiple layers of over-growing cells and high saturation densities. Cells also changed from fibroblast-like to a more spindle-shaped morphology, which was associated with a smaller cell size, a dramatic increase in cell polarization, a reduction in the number of actin stress fibres and less punctate labeling of focal adhesions. Analysis of single cell migration and scratch wound closure clearly demonstrated that hERG1-expressing cells migrated more rapidly than vector-transfected control cells. In contrast to previous studies on hEAG1, there were no increases in rates of proliferation, or loss of growth factor-dependency, however, hERG1-expressing cells were capable of substrate-independent growth. Allogeneic transplantation of hERG1-expressing cells into nude mice resulted in an increased incidence of tumors. In contrast to hEAG1, the mechanism of cellular transformation is dependent on ion conduction. Trafficking deficient and conduction deficient hERG1 mutants also prevented cellular transformation. These results provide evidence that hERG1 expression is sufficient to induce cellular transformation by a mechanism distinct from hEAG1. Importantly, selective hERG1 channel blockers have therapeutic potential in the treatment of hERG1-expressing cancers.
    Full-text · Article · May 2014 · Molecular pharmacology
  • Source
    • "Similarly, targeting the big conductance K+ channel with the inhibitor tetraethyl ammonium attenuates cisplatin-induced apoptosis in type I spiral ligament fibrocytes [43] and mouse neocortical neurons [44]. The TASK3 gene (Kcnk9) is overexpressed in several types of human carcinomas which has been associated with resistance towards apoptosis [45]. This is in contrast to what is seen in different glioma cell lines where application of the TASK3 channel opener isoflurane significantly reduces cell survival and the TASK channel blockers bupivacaine and spermine completely reverses this effect [46]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multi-drug resistance (MDR) to chemotherapy is the major challenge in the treatment of cancer. MDR can develop by numerous mechanisms including decreased drug uptake, increased drug efflux and the failure to undergo drug-induced apoptosis. Evasion of drug-induced apoptosis through modulation of ion transporters is the main focus of this paper and we demonstrate how pro-apoptotic ion channels are downregulated, while anti-apoptotic ion transporters are upregulated in MDR. We also discuss whether upregulation of ion transport proteins that are important for proliferation contribute to MDR. Finally, we discuss the possibility that the development of MDR involves sequential and localized upregulation of ion channels involved in proliferation and migration and a concomitant global and persistent downregulation of ion channels involved in apoptosis.
    Full-text · Article · Mar 2014 · Philosophical Transactions of The Royal Society B Biological Sciences
Show more